U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

PerkinElmer, Inc. (PKI)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
68.17-0.03 (-0.04%)
At close: 4:03PM EDT

68.17 0.00 (0.00%)
After hours: 4:42PM EDT

People also watch
WATPDCOTMOPNWRHI

PerkinElmer, Inc.

940 Winter Street
Waltham, MA 02451
United States
781-663-6900
http://www.perkinelmer.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees8,000

Key Executives

NameTitlePayExercisedAge
Mr. Robert F. FrielChairman, Chief Exec. Officer and Pres5.05M13.87M61
Mr. Frank A. WilsonChief Financial Officer and Sr. VP1.59M2.56M58
Mr. Joel S. GoldbergSr. VP of Admin., Gen. Counsel and Sec.1.36M2.1M48
Mr. James CorbettExec. VP and Pres of Discovery & Analytical Solutions1.26M42.84k54
Mr. Prahlad R. SinghSr. VP and Pres of Diagnostics852.93kN/A52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates through two segments, Discovery and Analytical Solutions and Diagnostics. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, food, lubricant, petrochemical, and polymer industries; and laboratory services. This segment’s offers a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. Its research portfolio includes a range of systems consisting of imaging, detection, and extraction instrumentation for use on in vitro, ex vivo, and in vivo models, analysis hardware, and software; and a range of consumable products, including drug discovery and research reagents. The Diagnostics segment provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. This segment also develops technologies that enable and support sample-to-sequencer workflow using next-generation DNA sequencing for applications in oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

Corporate Governance

PerkinElmer, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.